Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 77 | 2024 | 5799 | 10.560 |
Why?
|
Carcinoma, Basal Cell | 22 | 2024 | 559 | 8.150 |
Why?
|
Carcinoma, Squamous Cell | 44 | 2024 | 4021 | 8.060 |
Why?
|
Mohs Surgery | 17 | 2024 | 221 | 2.930 |
Why?
|
Neoplasm Staging | 25 | 2024 | 11083 | 1.300 |
Why?
|
Acitretin | 2 | 2023 | 16 | 0.970 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2024 | 9245 | 0.850 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2023 | 27 | 0.840 |
Why?
|
Keratosis, Actinic | 2 | 2020 | 72 | 0.830 |
Why?
|
Skin | 8 | 2023 | 4464 | 0.820 |
Why?
|
Photochemotherapy | 4 | 2022 | 819 | 0.810 |
Why?
|
Eyelid Neoplasms | 1 | 2023 | 89 | 0.810 |
Why?
|
Sweat Glands | 1 | 2022 | 33 | 0.800 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2023 | 321 | 0.790 |
Why?
|
Head and Neck Neoplasms | 5 | 2024 | 2882 | 0.750 |
Why?
|
Keratolytic Agents | 1 | 2021 | 34 | 0.740 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2021 | 1788 | 0.740 |
Why?
|
Retrospective Studies | 40 | 2024 | 79982 | 0.700 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3167 | 0.640 |
Why?
|
Melanoma | 6 | 2024 | 5690 | 0.640 |
Why?
|
Psoriasis | 2 | 2023 | 938 | 0.630 |
Why?
|
Mouth Neoplasms | 1 | 2023 | 593 | 0.620 |
Why?
|
Neoplasm Invasiveness | 9 | 2024 | 3595 | 0.600 |
Why?
|
Organ Transplantation | 2 | 2024 | 1150 | 0.540 |
Why?
|
Humans | 94 | 2024 | 757650 | 0.540 |
Why?
|
Niacinamide | 3 | 2023 | 413 | 0.540 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 1051 | 0.500 |
Why?
|
Lymphatic Vessels | 1 | 2019 | 358 | 0.500 |
Why?
|
Medicare Part D | 1 | 2020 | 353 | 0.490 |
Why?
|
Insurance Claim Review | 1 | 2019 | 735 | 0.480 |
Why?
|
Salvage Therapy | 1 | 2021 | 1264 | 0.470 |
Why?
|
Clinical Protocols | 1 | 2020 | 1436 | 0.450 |
Why?
|
Antineoplastic Agents | 7 | 2023 | 13603 | 0.450 |
Why?
|
Blood Vessels | 1 | 2019 | 1112 | 0.450 |
Why?
|
Aftercare | 1 | 2019 | 909 | 0.440 |
Why?
|
Prognosis | 14 | 2023 | 29493 | 0.430 |
Why?
|
Health Care Costs | 3 | 2023 | 3234 | 0.410 |
Why?
|
Prescription Drugs | 1 | 2020 | 626 | 0.410 |
Why?
|
Dermatology | 3 | 2020 | 914 | 0.410 |
Why?
|
Cohort Studies | 18 | 2024 | 41198 | 0.410 |
Why?
|
Health Expenditures | 4 | 2021 | 2342 | 0.410 |
Why?
|
Immunotherapy | 6 | 2024 | 4641 | 0.400 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2796 | 0.380 |
Why?
|
Sarcoma | 1 | 2022 | 1784 | 0.370 |
Why?
|
Carcinoma | 1 | 2022 | 2330 | 0.360 |
Why?
|
Chemoprevention | 2 | 2023 | 326 | 0.340 |
Why?
|
Kidney Transplantation | 2 | 2024 | 4214 | 0.330 |
Why?
|
Nervous System Neoplasms | 2 | 2020 | 91 | 0.330 |
Why?
|
Combined Modality Therapy | 4 | 2023 | 8515 | 0.330 |
Why?
|
Injections, Intralesional | 2 | 2020 | 277 | 0.330 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2417 | 0.320 |
Why?
|
Keratinocytes | 3 | 2021 | 790 | 0.320 |
Why?
|
Arthritis, Rheumatoid | 1 | 2023 | 3753 | 0.300 |
Why?
|
Medicare | 4 | 2023 | 6717 | 0.290 |
Why?
|
Primary Health Care | 1 | 2024 | 4651 | 0.290 |
Why?
|
Aged | 26 | 2024 | 167889 | 0.290 |
Why?
|
Female | 37 | 2024 | 389985 | 0.270 |
Why?
|
Male | 36 | 2024 | 358227 | 0.270 |
Why?
|
Hedgehog Proteins | 4 | 2023 | 768 | 0.260 |
Why?
|
Fluorouracil | 3 | 2022 | 1636 | 0.250 |
Why?
|
Lymphatic Metastasis | 3 | 2022 | 2915 | 0.240 |
Why?
|
Patient Selection | 1 | 2016 | 4235 | 0.230 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58559 | 0.230 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2809 | 0.220 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1113 | 0.220 |
Why?
|
Mass Screening | 1 | 2019 | 5413 | 0.220 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5325 | 0.220 |
Why?
|
Philadelphia | 1 | 2023 | 265 | 0.210 |
Why?
|
United States | 12 | 2023 | 71907 | 0.210 |
Why?
|
Hospitals, Private | 2 | 2010 | 63 | 0.200 |
Why?
|
Computers, Handheld | 1 | 2024 | 209 | 0.200 |
Why?
|
Pilot Projects | 3 | 2024 | 8551 | 0.190 |
Why?
|
Middle Aged | 19 | 2024 | 219219 | 0.190 |
Why?
|
Tranexamic Acid | 1 | 2024 | 176 | 0.190 |
Why?
|
Skin Pigmentation | 2 | 2020 | 276 | 0.190 |
Why?
|
Hospitals, Public | 2 | 2010 | 201 | 0.180 |
Why?
|
Arthritis, Psoriatic | 1 | 2013 | 219 | 0.180 |
Why?
|
Antifibrinolytic Agents | 1 | 2024 | 292 | 0.180 |
Why?
|
Hospitals | 3 | 2023 | 3861 | 0.180 |
Why?
|
Postoperative Hemorrhage | 1 | 2024 | 412 | 0.180 |
Why?
|
Pyloric Stenosis | 1 | 2010 | 28 | 0.170 |
Why?
|
Treatment Outcome | 10 | 2024 | 64242 | 0.170 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4888 | 0.170 |
Why?
|
Risk Factors | 8 | 2024 | 73716 | 0.170 |
Why?
|
Dermatologic Agents | 1 | 2013 | 308 | 0.170 |
Why?
|
Health Services Needs and Demand | 2 | 2015 | 1399 | 0.170 |
Why?
|
Risk Assessment | 5 | 2024 | 23819 | 0.170 |
Why?
|
Diagnostic Imaging | 3 | 2023 | 3524 | 0.170 |
Why?
|
Scalp | 1 | 2012 | 389 | 0.160 |
Why?
|
Algorithms | 1 | 2019 | 13952 | 0.160 |
Why?
|
Calcitriol | 1 | 2020 | 297 | 0.160 |
Why?
|
September 11 Terrorist Attacks | 1 | 2009 | 105 | 0.160 |
Why?
|
Ultraviolet Rays | 2 | 2020 | 1076 | 0.150 |
Why?
|
Organizational Innovation | 1 | 2021 | 536 | 0.150 |
Why?
|
Curriculum | 2 | 2023 | 3715 | 0.150 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 711 | 0.150 |
Why?
|
Hospitals, University | 1 | 2009 | 564 | 0.140 |
Why?
|
Cisplatin | 1 | 2023 | 1647 | 0.140 |
Why?
|
Sensitivity and Specificity | 2 | 2024 | 14638 | 0.140 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3667 | 0.130 |
Why?
|
Skin Diseases | 2 | 2015 | 1088 | 0.130 |
Why?
|
Drug Synergism | 1 | 2020 | 1746 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2511 | 0.130 |
Why?
|
Aminoquinolines | 1 | 2015 | 108 | 0.120 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1667 | 0.120 |
Why?
|
Cryosurgery | 1 | 2020 | 474 | 0.120 |
Why?
|
Radiotherapy | 1 | 2022 | 1498 | 0.120 |
Why?
|
Drugs, Generic | 1 | 2020 | 444 | 0.120 |
Why?
|
Physician's Role | 1 | 2021 | 916 | 0.120 |
Why?
|
Sex Factors | 3 | 2024 | 10497 | 0.110 |
Why?
|
Lymph Nodes | 2 | 2023 | 3474 | 0.110 |
Why?
|
Trauma Centers | 1 | 2009 | 933 | 0.110 |
Why?
|
Child Health Services | 1 | 2009 | 644 | 0.110 |
Why?
|
Education, Medical, Graduate | 2 | 2023 | 2355 | 0.110 |
Why?
|
Disaster Planning | 1 | 2009 | 557 | 0.110 |
Why?
|
Follow-Up Studies | 5 | 2023 | 39018 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 759 | 0.100 |
Why?
|
Appendicitis | 1 | 2009 | 674 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1788 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 25931 | 0.100 |
Why?
|
Drug Costs | 1 | 2020 | 1179 | 0.100 |
Why?
|
Clinical Competence | 2 | 2019 | 4760 | 0.100 |
Why?
|
Incidence | 5 | 2024 | 21217 | 0.090 |
Why?
|
Diagnosis, Differential | 2 | 2024 | 12950 | 0.090 |
Why?
|
Adult | 10 | 2024 | 219747 | 0.090 |
Why?
|
Recurrence | 1 | 2022 | 8426 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1903 | 0.090 |
Why?
|
Edema | 1 | 1994 | 769 | 0.090 |
Why?
|
Patient Compliance | 1 | 2010 | 2685 | 0.090 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2743 | 0.080 |
Why?
|
Eosinophilia | 1 | 1994 | 559 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2019 | 2167 | 0.080 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12400 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2308 | 0.080 |
Why?
|
Internship and Residency | 2 | 2021 | 5854 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2495 | 0.080 |
Why?
|
Survival Rate | 2 | 2019 | 12685 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1915 | 0.070 |
Why?
|
Survival Analysis | 4 | 2023 | 10075 | 0.070 |
Why?
|
New York City | 2 | 2010 | 726 | 0.070 |
Why?
|
Veterans | 1 | 2021 | 2629 | 0.070 |
Why?
|
Boston | 1 | 2019 | 9297 | 0.070 |
Why?
|
Reoperation | 1 | 2016 | 4279 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11709 | 0.070 |
Why?
|
Registries | 2 | 2019 | 8164 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20499 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7366 | 0.060 |
Why?
|
Pneumonia, Viral | 1 | 2021 | 3197 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10135 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15209 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 678 | 0.050 |
Why?
|
Radioimmunotherapy | 1 | 2012 | 91 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13267 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22024 | 0.050 |
Why?
|
Antigens, Nuclear | 1 | 2012 | 184 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2009 | 5382 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8601 | 0.050 |
Why?
|
Pamphlets | 1 | 2021 | 71 | 0.050 |
Why?
|
Amides | 1 | 2023 | 447 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 36271 | 0.050 |
Why?
|
Models, Econometric | 1 | 2021 | 216 | 0.040 |
Why?
|
Squalene | 1 | 2019 | 35 | 0.040 |
Why?
|
Joint Diseases | 1 | 2013 | 457 | 0.040 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 151 | 0.040 |
Why?
|
Anilides | 1 | 2022 | 409 | 0.040 |
Why?
|
Vitamin B Complex | 1 | 2021 | 298 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 733 | 0.040 |
Why?
|
Photosensitizing Agents | 1 | 2022 | 618 | 0.040 |
Why?
|
Research Design | 2 | 2024 | 6151 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 39815 | 0.040 |
Why?
|
Germany | 1 | 2019 | 865 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3415 | 0.030 |
Why?
|
Ligands | 1 | 2023 | 3258 | 0.030 |
Why?
|
Remission Induction | 1 | 2022 | 2391 | 0.030 |
Why?
|
Australia | 1 | 2019 | 1235 | 0.030 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2019 | 447 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2022 | 1384 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2017 | 6808 | 0.030 |
Why?
|
Appendectomy | 1 | 2009 | 430 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 419 | 0.030 |
Why?
|
Disease Progression | 2 | 2023 | 13464 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1870 | 0.030 |
Why?
|
Lichenoid Eruptions | 1 | 1994 | 13 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1174 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2019 | 1036 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 1994 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 1722 | 0.030 |
Why?
|
Blister | 1 | 1994 | 86 | 0.030 |
Why?
|
Video Recording | 1 | 2019 | 954 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1557 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1518 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1887 | 0.030 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 1994 | 85 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2847 | 0.030 |
Why?
|
Exocytosis | 1 | 1994 | 319 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1402 | 0.030 |
Why?
|
Radiosurgery | 1 | 2012 | 1341 | 0.030 |
Why?
|
Pemphigoid, Bullous | 1 | 1994 | 114 | 0.030 |
Why?
|
Dermatitis | 1 | 1994 | 200 | 0.030 |
Why?
|
Complement C3 | 1 | 1994 | 451 | 0.030 |
Why?
|
Brachytherapy | 1 | 2019 | 1224 | 0.020 |
Why?
|
Social Class | 1 | 2010 | 1995 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18328 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2305 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 21990 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13265 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2919 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2012 | 3608 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 1994 | 2470 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2504 | 0.020 |
Why?
|
Laryngeal Cartilages | 1 | 1989 | 23 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 793 | 0.020 |
Why?
|
Cricoid Cartilage | 1 | 1989 | 69 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2019 | 2976 | 0.020 |
Why?
|
Mortality | 1 | 2020 | 2881 | 0.020 |
Why?
|
Influenza, Human | 1 | 2019 | 1516 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5481 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2021 | 3239 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3356 | 0.020 |
Why?
|
Laparoscopy | 1 | 2009 | 2032 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54108 | 0.020 |
Why?
|
Child | 3 | 2010 | 79787 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3839 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2019 | 4738 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7982 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4550 | 0.020 |
Why?
|
Length of Stay | 1 | 2010 | 6384 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10478 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 2010 | 7801 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8815 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2012 | 9163 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7799 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2010 | 3319 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2019 | 4308 | 0.010 |
Why?
|
Airway Obstruction | 1 | 1989 | 661 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15641 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9624 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1994 | 4540 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22008 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9979 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2012 | 8981 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13222 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2010 | 26173 | 0.010 |
Why?
|
Adolescent | 2 | 2009 | 87832 | 0.010 |
Why?
|
Infant | 1 | 2010 | 36043 | 0.010 |
Why?
|
Child, Preschool | 1 | 2009 | 42044 | 0.010 |
Why?
|
Mice | 1 | 2019 | 81107 | 0.010 |
Why?
|
Succinylcholine | 1 | 1989 | 66 | 0.010 |
Why?
|
Animals | 1 | 2019 | 167777 | 0.000 |
Why?
|
Intubation, Intratracheal | 1 | 1989 | 1327 | 0.000 |
Why?
|
Heart Arrest | 1 | 1989 | 1494 | 0.000 |
Why?
|
Respiration, Artificial | 1 | 1989 | 2619 | 0.000 |
Why?
|
Concepts
(252)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(54)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_